When the IPO Window Narrows Your Strategy Matters More


The IPO window has a habit of moving just as management reaches for the handle.
A few weeks ago, the conversation was about a revival. Now, a growing list of postponed deals is testing that enthusiasm. For international companies considering the US, this deserves more than a revised roadshow calendar.
It deserves a fresh look at the plan.
I would be careful about declaring the entire market closed. Markets rarely send everyone the same invitation. But a market that remains available to some companies can still be effectively shut to yours.
The headlines have changed
Reuters reported on October 9th that several high-profile offerings have been delayed or withdrawn. Oura postponed its planned US IPO in September. Holtec Nuclear withdrew its offering that month. Bamboo Insurance also postponed. In Australia, Firmus withdrew its planned listing in October and said it would pursue private funding and consider other listing options.
That is a meaningful warning. It is not proof that every IPO is off the table.
EY’s October 13th review described a resilient global third quarter, with broader sector participation and continued investor appetite for quality offerings. A strong quarter and a difficult few weeks can coexist. Neither tells an individual board what valuation it can achieve tomorrow.
My read is that issuers should plan for a more demanding market. Investors can like the business and dislike the price. They can also like both and decide to wait.
Your timetable may be urgent. Their timetable usually isn’t
Start with cash and a realistic valuation
Before debating the exchange, ask what happens if the deal slips six months. Or twelve.
Can the business fund its next milestones? What spending can move? What financing alternatives are genuinely available? What dilution would management accept? Those questions are easier to answer before the cash balance starts chairing the board meeting.
Then revisit valuation. Use relevant public peers, their current trading levels and the risks investors are being asked to take. The last private funding round is useful context. It is not a standing instruction to the public market.
A lower valuation can be painful. An underfunded business waiting for an old valuation to return can be worse. Equally, accepting any price simply to complete a listing is hardly a strategy.
Capital is global so think globally
The US should earn its place in your capital markets strategy. However, capital is global. Your choice of IPO market should reflect that.
There is no shortage of advisers ready to sell a US IPO. It is a lucrative business. However, boards should ask how advisers are paid and incentivized, what, if any, alternatives they have assessed and whether the recommendation serves the long-term interests of the company or the short term interests of the advisors pay-packet.
The adviser gets paid when the deal closes. Management still has to explain the share price a year later. Those are different scorecards.
Compare the US with your home market and other credible venues in Europe, Asia and the Middle East. Look at companies of your size and sector. Who owns them? Who covers them? How much actually trades? What does it cost to remain public? Does your cap-table really support a successful US listing?
A smaller market with investors who understand your business may offer a better IPO outcome and a healthier secondary market. That needs testing, not assuming. The biggest pool of capital is not automatically the deepest pool for your shares.
You can also reach international investors from a home-market listing. The location of your ticker need not define the geography of your shareholders.
Choose the market where you can build sustained demand. A photograph in Times Square or on Wall Street is a nice souvenir. It is not a liquidity strategy.
US investor access needs its own plan
For an international issuer, the appeal of the US remains clear. A large pool of capital. A broad investor base. Potential customers, partners and acquisition opportunities.
But those benefits require work. A ticker does not create an audience. The opening bell is excellent theatre. It is a fairly limited investor relations department.
Who can realistically own your shares? Which funds invest in your sector and at your size? Can brokers support the security? Is there enough free float for investors to build positions? How will research and regular communication help people understand the business?
These questions matter before an offering. They matter even more after it.
A smaller foreign company also needs to explain what a US investor may not know: the home market, governance, currency exposure and how the business compares with familiar alternatives. Management’s job is to make the investment case understandable and the shares practical to own.
Keep working while the timetable moves
For companies already listed outside the US, an IPO is only one possible route to a broader shareholder base. Depending on the company and its objectives, an ADR program, an OTC trading presence or a later exchange listing may deserve consideration. So may stronger investor access in another global market, either first or alongside the US.
These routes do different jobs. An OTC quotation or a Level I ADR program does not itself raise fresh capital. Nor does another ticker guarantee liquidity. Costs, eligibility, reporting obligations and the connection with the home market all need proper assessment.
For a private company, the alternatives will be different. Private funding, a strategic investor or a revised listing timetable may offer a better fit. Each carries its own trade-offs.
The point is to have choices before you need them.
Use the time to sharpen the equity story. Improve disclosure. Identify investors. Address trading barriers. Build a credible communications plan. Decide what would justify proceeding and what would make you pause.
After more than 20 years in cross-border equities, I have seen how much attention goes into completing the transaction. The harder work is building an investor base that stays interested once the transaction is over.
At Crossbridge Advisors, we help companies assess their US and global capital markets options and turn them into a practical execution plan. That includes deciding whether to proceed, prepare or take another route.
If you and your board is weighing where to IPO, reconsidering a US listing or finding that its existing market delivers less access than expected, let’s talk.
The IPO window may move. Your strategy should be able to move with it.




Comments